

Disclosures

Dr. Blier has received research support or speakers honoraria from or served as a consultant to, Allergan, Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Pierre Fabre Medicaments, Pfizer, Shire, and Takeda. Drs. Phillips, Knott, and de la Salle report no financial interests or potential conflicts of interest.

Declaration of Competing Interest

None.

Acknowledgments

Presented in part at the Canadian College of Neuropsychopharmacology 40th Annual Meeting, Kingston, Ontario, June 7- 9, 2017 and at the Society of Biological Psychiatry 73rd Annual Scientific Convention and Program, New York, May 10–12, 2018.

The clinical trial was funded by the Canadian Institutes of Health Research (grant 274324 to Dr. Blier) and a Tier 1 Canada Research Chair (to Dr. Blier). Electrophysiological work was supported by an Ontario Mental Health Foundation (OMHF) studentship awarded to Dr. de la Salle.

The authors would like to thank Molly Hyde, Ashley Baddeley, and Renée Baysarowich from the Clinical EEG & Neuroimaging Research Lab, as well as Dr. Sandhaya Norris, Dr. Jeanne Talbot, Dr. Lisa Batten, Wendy Fusee, Holly English, and Maria da Silva from the Mood Disorders Research Unit.